Severe symptomatic osteoporosis in patients on androgen deprivation therapy for prostatic carcinoma.
We report 3 patients referred to the bone clinic after spinal fractures. Dual energy X-ray absorptiometry showed severe osteoporosis. Each patient was found to have a history of prostatic carcinoma and long-term treatment with goserelin. We suggest that all patients who have received androgen deprivation therapy for more than 1 year should be evaluated by bone densitometry.
Paterson
C R
CR
Department of Medicine, University of Dundee, UK. c.r.paterson@dundee.ac.uk
Mole
P A
PA
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D003720:Densitometry; D005264:Femoral Fractures / Q000175:diagnosis / Q000209:etiology; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000175:diagnosis / Q000209:etiology*; D017273:Goserelin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018570:Risk Assessment; D012720:Severity of Illness Index; D016103:Spinal Fractures / Q000175:diagnosis / Q000209:etiology; D013904:Thoracic Vertebrae / Q000293:injuries
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin